Dopaminergic Neuron Screening via Fluorescent Dopamine Analog
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for screening compounds for therapeutic effects on dopaminergic neurons are hindered by high costs and time limitations in mammalian animal models, necessitating the development of a cell-based high-throughput screening system.
Innovation Solution
A method involving labeling dopaminergic neurons with a fluorescent dopamine analog, measuring fluorescence levels, and exposing them to potential agents to determine neuroeffector properties, utilizing ex vivo differentiated pluripotent stem cells and specific differentiation agents like FGF8 and Purmorphamine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mammalian animal models are used for screening compounds, then reliability of therapeutic effect identification is improved, but cost and time consumption increase significantly
Solution Approach 1:
The patent creates a cell-based model that copies the essential functional characteristics of dopaminergic neurons in mammalian systems. By using cell lines expressing human dopamine transporters and receptors, the invention replicates key neurobiological processes in a simplified, high-throughput format that maintains biological relevance while enabling rapid screening of large compound libraries
Solution Approach 2:
The invention extracts the critical dopaminergic neuronal functions from complex mammalian animal models and isolates them into a cell-based assay system. By focusing specifically on dopamine transporter-mediated uptake and dopamine receptor signaling in cultured cells, the patent separates the essential therapeutic effect detection from the time-consuming and expensive animal model requirements
2Measurement precision
If fluorescent dopamine analogs are used for labeling, then detection sensitivity is improved, but background fluorescence from non-dopaminergic cells increases
Solution Approach 1:
The patent segments the detection process into two distinct stages: first, labeling dopaminergic neurons with fluorescent dopamine analogs to establish baseline fluorescence; second, applying test compounds and measuring changes in fluorescence. This segmentation allows differentiation between background fluorescence (present in both stages) and specific drug-induced changes (detected as differential signals), thereby improving signal-to-noise ratio
Solution Approach 2:
The invention employs a feedback mechanism by measuring fluorescence at multiple time points - before and after compound treatment. The baseline measurement provides feedback that enables normalization and correction of background fluorescence, allowing accurate quantification of drug-specific effects on dopaminergic neuron function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables effective identification of neuroprotective and regenerative compounds for Parkinson's disease treatment by quantifying fluorescence changes indicative of neuroeffector activity, facilitating the screening of large libraries for therapeutic compounds.
Implementation Method 1
labeling dopaminergic neurons with a fluorescent dopamine analog
Implementation Method 2
a fluorescent dopamine analog... which is actively transported into the cells via the neurotransmitter transporters
Implementation Method 3
measuring a level of fluorescence in the mixed population of cells... a change in the level of fluorescence is indicative of the substance being a neuroeffector
Data Source
Figure 1
Figure 2A~2C
Figure 3A~3D
AI summary
A method of determining whether an agent is a neuroeffector is disclosed. The method comprises: (a) labeling dopaminergic neurons which are comprised in a mixed population of cells with a fluorescent dopamine analog; (b) measuring a level of fluorescence in the mixed population of cells; (c) exposing the mixed population of cells to the agent; (d) remeasuring a level of fluorescence in the mixed population of cells, wherein a change in the level of fluorescence is indicative of the substance being a neuroeffector.